Table 2.
Site of Active Cancer in All Patients and in Patients Treated With Each DOAC Separately
| All (n=323) |
DOAC therapy | ||||
|---|---|---|---|---|---|
| Edoxaban (n=234) |
Apixaban (n=50) |
Rivaroxaban (n=39) |
P value | ||
| Uterus, adnexa | 88 (27.4) | 67 (28.6) | 13 (26.0) | 8 (20.5) | 0.560 |
| Gastrointestinal tract | 63 (19.5) | 44 (18.8) | 10 (20.0) | 9 (23.1) | 0.820 |
| Lung | 35 (10.8) | 25 (10.7) | 5 (10.0) | 5 (12.8) | 0.905 |
| Blood | 35 (10.8) | 24 (10.3) | 7 (14.0) | 4 (10.3) | 0.736 |
| Liver, bile duct, pancreas | 34 (10.5) | 26 (11.1) | 5 (10.0) | 3 (7.7) | 0.806 |
| Urinary, prostate | 22 (6.8) | 15 (6.4) | 5 (10.0) | 2 (5.1) | 0.556 |
| Oral cavity, pharynx, larynx | 19 (5.9) | 14 (6.0) | 0 (0.0) | 5 (12.8) | 0.027 |
| Brain | 12 (3.7) | 8 (3.4) | 4 (8.0) | 0 (0.0) | 0.169 |
| Breast | 9 (2.8) | 6 (2.6) | 1 (2.0) | 2 (5.1) | 0.552 |
| Others | 6 (1.9) | 5 (2.1) | 0 (0.0) | 1 (2.6) | 0.656 |
Unless indicated otherwise, data are presented as n (%). DOAC, direct oral anticoagulant.